Related Experiment Videos
Meeting the challenges of vascular dementia. Introduction
1UCLA NPI, Los Angeles, California, USA.
Insights
Diagnosing and managing vascular dementia (VaD) and Alzheimer's disease with cerebrovascular disease (CVD) presents challenges. Research is advancing to find treatments targeting shared pathophysiological mechanisms for improved patient outcomes.
Area of Science:
- Neurology
- Neuroscience
- Geriatrics
Background:
- Significant challenges exist in the diagnosis and management of vascular dementia (VaD) and Alzheimer's disease with cerebrovascular disease (CVD).
- These challenges complicate epidemiological studies, diagnostic guidelines, and optimal treatment strategies for a substantial patient population.
- Ongoing controversy highlights the need for clearer understanding and management approaches for these overlapping conditions.
Purpose of the Study:
- To address the difficulties in diagnosing and managing patients with VaD or Alzheimer's disease with CVD.
- To provide clinicians with updated information and insights into the shared pathophysiology of these conditions.
- To explore potential therapeutic targets based on common pathophysiological mechanisms.
Main Methods:
- An international group of physicians and researchers convened in March 2001 to discuss and resolve issues related to VaD and Alzheimer's disease with CVD.
- The discussion focused on shared pathophysiological mechanisms, including neurotransmitter abnormalities.
- Review of existing literature on randomized, controlled trials for agents targeting cognitive and noncognitive outcomes in these patient groups.
Main Results:
- VaD and Alzheimer's disease appear to share common pathophysiological mechanisms beyond simple coexistence.
- No agent has yet demonstrated broad efficacy in randomized, controlled trials for both cognitive and noncognitive outcomes in VaD and Alzheimer's disease with CVD.
- Recent advancements in understanding pathophysiology offer promising avenues for effective treatment development.
Conclusions:
- Treatments targeting the common pathophysiology of VaD and Alzheimer's disease with CVD hold therapeutic potential.
- Further research into shared mechanisms is crucial for developing effective interventions.
- Progress in understanding pathophysiology brings closer the prospect of effective treatments for Alzheimer's disease, coexisting CVD, and VaD.
Abstract:
Ongoing controversy over the challenges associated with the diagnosis and management of patients with vascular dementia (VaD) or Alzheimer's disease with cerebrovascular disease (CVD) has led to difficulties with establishing epidemiology and diagnostic guidelines, as well as deciding upon optimal management practices. In March 2001, an international group of physicians and researchers gathered to resolve some of these issues and provide clinicians with useful information relating to this large patient group. In addition to simple coexistence, VaD and Alzheimer's disease appear to share common pathophysiological mechanisms, such as neurotransmitter abnormalities. Treatments that target the common pathophysiology of the two conditions may prove useful. To date, no reports have been published of any agent demonstrating broad efficacy (on cognitive and noncognitive outcomes) in VaD and Alzheimer's disease with CVD in randomised, controlled trials. Recent developments in understanding the pathophysiology of the conditions, however, have taken researchers an important step closer to finding an effective treatment, not only for patients with Alzheimer's disease, but also for those with coexisting CVD and those with VaD.